Trials / Completed
CompletedNCT04825561
A Study to Evaluate the Efficacy and Safety of AD-208
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-208.
Detailed description
The purpose of this study is to evaluate the efficacy and safety of AD-208 in male patients with androgenetic alopecia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-208 | PO, Once daily(QD), 24weeks |
| DRUG | AD-2081 | PO, Once daily(QD), 24weeks |
| DRUG | placebo of AD-208 | PO, Once daily(QD), 24weeks |
| DRUG | placebo of AD-2081 | PO, Once daily(QD), 24weeks |
Timeline
- Start date
- 2021-06-09
- Primary completion
- 2023-01-09
- Completion
- 2023-06-01
- First posted
- 2021-04-01
- Last updated
- 2023-07-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04825561. Inclusion in this directory is not an endorsement.